hotspot -WSS

hotspot

author：entertainment 2025-09-28 20:33:08 - browse：2

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： HCA says smaller share of spending going to labor

hotspot

WSS

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

HIV drugs protect against transmission, even in unprotected sex

House GOP plan to stem drug shortages differs from Democrats’

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

hotspot

hotspot

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Shifting the focus from loneliness to social health

How one medical school became remarkably diverse

HCA says smaller share of spending going to labor

Hepatitis C has a cure — but many Americans still lack access to it

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

23andMe had bad news about my health. I wish a person had delivered it

Ultragenyx gene therapy for rare liver ailment succeeds in late

The high cost of giving birth even with insurance

Intellia reports positive results for its CRISPR

focus

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Poland's lawmakers approve a divisive law on Russian influence

5 wounded, 2 critically, in Michigan shopping center shooting

Ionis drug prevents swelling attacks due to hereditary angioedema

Innovation in antibiotics is ailing. 'Brain drain' may kill it

What AstraZeneca

Wikipedia

entertainment

hotspot

hotspot